Research interest leads first participant to join groundbreaking TOPPLE T1D study
|
TrialNet Research Continues to Close in on Type 1 Diabetes Prevention
New TrialNet research findings published today in Science Translational Medicine show that a 14-day course of the immunotherapy drug teplizumab provided an additional year of delay in onset of type 1 diabetes and improved insulin production, increasing the overall benefit to high-risk individuals reported in the original study fin
TrialNet Launches New Study Exploring Plasmid Therapy
Now enrolling adults diagnosed with T1D in the past 4 years
TrialNet is excited to announce the launch of our first Phase 1 clinical study to test a new plasmid therapy. The study will enroll 48 adults (age 18-45) diagnosed with type 1 diabetes (T1D) in the past 4 years.